Yamagata Kenji, Onizawa Kojiro, Otsuka Yuki, Yoshida Hiroshi
Department of Oral and Maxillofacial Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
Oral Maxillofac Surg. 2008 May;12(1):13-8. doi: 10.1007/s10006-008-0100-1.
The aims of the study were to investigate the prognosis of patients with lung metastasis after treatment for head and neck squamous cell carcinoma (HANSCC) and to preliminarily evaluate the efficacy and toxicity of docetaxel (DOC)-based chemotherapy.
The effectiveness of the chemotherapy was evaluated retrospectively according to the tumor response rate and survival time post-metastasis. Thirty patients were enrolled in the study. Twenty-seven have died, two are living, and one was lost during follow-up. Nineteen patients were treated for lung metastasis with chemotherapy. DOC-based chemotherapy was given to seven patients and non-DOC-based chemotherapy to 12.
The response rate was 28.6% for the first administration of DOC-based chemotherapy, but only 8.3% for the non-DOC-based chemotherapy. Thus, DOC-based chemotherapy had a better response rate for lung metastases than other chemotherapy agents tested. Although the sample size was small, DOC seems to shrink or inhibit the growth of lung metastases in patients with primary HANSCC.
本研究旨在调查头颈部鳞状细胞癌（HANSCC）治疗后发生肺转移患者的预后，并初步评估以多西他赛（DOC）为基础的化疗的疗效和毒性。
根据肿瘤缓解率和转移后的生存时间对化疗效果进行回顾性评估。30例患者纳入本研究。27例患者死亡，2例存活，1例在随访期间失访。19例患者接受了针对肺转移的化疗。7例患者接受了以DOC为基础的化疗，12例接受了非DOC为基础的化疗。
首次给予以DOC为基础的化疗时缓解率为28.6%，而非DOC为基础的化疗缓解率仅为8.3%。因此，与其他受试化疗药物相比，以DOC为基础的化疗对肺转移有更好的缓解率。尽管样本量较小，但DOC似乎能使原发性HANSCC患者的肺转移瘤缩小或抑制其生长。
